By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German chemoproteomics firm Cellzome today announced a collaboration with Pfizer to study epigenetic mechanisms involved in stem cell differentiation.

Cellzome will use its Episphere platform to characterize epigenetic changes while Pfizer's Pain & Sensory Disorders and Regenerative Medicine unit, Neusentis, will provide expertise in stem-cell handling and regenerative medicine.

Financial and other terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.